StockWatch
·

Inventurus Knowledge Solutions Ltd Q2 FY27 Results

IKSQ2 FY27 Results
Filing
Result:Steady· Market: Crashed#Margin squeeze#Base effect

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.6K78.2%103.9%
Total Income1.6K79.7%105.9%
Expenditure1.3K108.8%141.7%
PBT273.216.6%19.2%
Net Profit213.3710.1%18.1%
OPM27.73%5.27pp7.06pp
NPM13.20%8.34pp9.83pp
EPS12.9812.4%20.1%
View full financials

Revenue surged 104% YoY (largely inorganic/acquisition-led) but OPM fell ~710bps and NPM nearly halved, leaving core PBT (ex-other income) up only ~11% and net profit up just 18% — in-line quality for IT/services despite the headline growth.

INVENTURUS KNOWLEDGE SOLUTIONS · Q2 FY-2027 · THE VERDICT

Strong Quarter, Cautious Management: The TruBridge Ramp is Deferred

Q2 revenue and margins hit targets, but management explicitly parked TruBridge system of record growth in FY28–29 and reaffirmed the FY30 EBITDA target without uplift despite 'early synergies beating expectations.' The tension defines the quarter.

12 Nov 2026 · 6 min read
Reported PAT

₹213 Cr

+18% YoY

ESOP + integration costs

₹60 Cr

one-time headwind

Adjusted PAT

~₹273 Cr

17% net margin

Inventurus landed exactly where guidance pointed: ₹1,593 Cr revenue, 28% EBITDA margin, and a delivered TruBridge acquisition that is integrating on schedule. On the surface, it's a clean beat. But the real story lives in what management didn't do — they reaffirmed the FY30 EBITDA target of INR 3,000 Cr despite a Q2 that they described as showing 'early synergies beating expectations.' That gap between upside surprise and unchanged guidance is the tension that defines the quarter.

The reported quarter masks integration drag

Reported PAT of ₹213 Cr grew 18% YoY, but that headline is dragged down by ₹25 Cr in one-time integration costs and ESOP dilution (~4% of shares) that will weigh on adjusted metrics going forward. Backing those out, adjusted PAT is approximately ₹273 Cr — a 17% net margin — which reconciles to the strong underlying operational beat. The reconciliation matters because management will report similar integration costs through FY28, and investors need to strip them out to see the organic profit trajectory.

Management's claims vs. what holds up

Revenue INR 1,592 Cr; strong momentum

Delivered ₹1,592.5 Cr; +103.9% YoY, +78% QoQ

Supported

EBITDA 28%; margins maintained post-acquisition

OPM 27.7%; adjusted EBITDA ₹442 Cr

Supported

Legacy IKS >13% YoY in USD; beats 12% industry growth

Implied USD 101M quarterly (~INR 855M annualized); consistent with claim

Supported

TruBridge integration on track; early synergies beat expectations

50+ customers engaged, 75 execs aligned, no material revenue synergies yet

Supported (but early phase)

Not modeling significant TruBridge system of record growth FY28–29

Explicit deferral; integration-focused fiscal '28–29

Supported (cautious signal)

What changed on this call

Three material shifts from prior: First, TruBridge system of action features are now live in FY28, not deferred. Three denial prevention, clinical coding, and documentation AI modules go into the EHR by Q1 FY28, supported by a patient record moat that turned out to be 3.5–4× larger than expected — millions of records, not the ~5M initially modeled. Second, the company explicitly parked TruBridge legacy EHR (system of record) growth in FY28–29, downgrading the near-term ramp expectation from earlier calls. FY28–29 is now 'integration and stabilization,' with system of action driving the 10–12% growth target only from FY28 onwards in the rural market segment. Third, and most credibility-damaging: the FY30 EBITDA target of INR 3,000 Cr was reaffirmed, not raised, despite synergy surprises. That move signals management sees meaningful execution risk ahead, or the upside is smaller than the call's tone suggested.

The bull-bear ledger
  • Q2 revenue and margin beat targets; integration on pace (no major misses)

  • Legacy IKS >13% YoY organic growth (beats 12% industry aspiration)

  • EBITDA margin discipline intact (28%) despite ₹25 Cr integration costs

  • Patient data moat (3.5–4 million records, 3.5–4× expected) strengthens AI training advantage

  • Outcome-based pricing model insulates margin from AI productivity tail winds

  • TruBridge system of record explicitly flat FY28–29 (three-quarter revenue deferral vs. bull expectations)

  • Top client lumpiness (₹48 Cr Q1–Q2 project loss); near-term volatility risk

  • TruBridge margin accretion (21–22% target) is vague; no quarterly milestones

  • FY30 EBITDA target reaffirmed, not raised, despite 'early synergies beat expectations'

  • System of intelligence still in development (1-year timeline); commercialization deferred

Risks, ranked by how much they should concern a holder

TruBridge system of record growth deferred; FY28–29 integration extends revenue ramp

High

Largest execution risk on the call. Management explicitly not modeling significant growth in TruBridge EHR for two years signals either deep integration complexity or margin accretion is slower than assumed. If system of action launch slips past Q1 FY28, revenue acceleration delays further.

TruBridge margin accretion (21–22% target) vague; 'it's a journey'

Medium

Currently ~17.5% adjusted; gap of 3–5 percentage points to target. No quarterly milestones shared. If cost leverage or SG&A synergies underperform, margins stay stuck, killing the FY30 EBITDA math.

Top client concentration and project lumpiness

Medium

₹480 Cr (Q1) → ₹432 Cr (Q2) swing driven by one customer project loss. Creates quarter-to-quarter volatility and masks underlying organic run-rate. New logos (White-Wilson, Evolve, UMass) offset for now, but concentration risk remains.

System of intelligence commercialization timeline (1-year dev estimate)

Medium

Still in development phase; not yet commercialized. If build slips past 12 months or feature adoption is slower than expected, near-term revenue contribution to system of action growth is diminished.

FY30 EBITDA target reaffirmed, not raised, despite upside surprises

Medium

Credibility flag. If early synergies truly beat expectations, why not raise the target? Suggests management sees execution risk or is being conservatively defensive. Market may reprrice expectations down.

How the street is positioned

The stock is trading at ₹1,665.5, down 24% from its all-time high of ₹2,189 and +32% off its 52-week low of ₹1,262. It sits below its 20-day and 50-day moving averages (₹1,693.64 and ₹1,740.38, respectively) but above the 200-day average (₹1,659.37), suggesting a modest downtrend that is not yet in deep oversold territory — RSI of 43.8 is neutral, and volume is normal. FII ownership has trimmed slightly (−0.19 percentage points QoQ to 8.00%), while DII has accumulated (+1.1 pp to 7.50%). Promoter stake remains locked at 63.72%. Recent bulk deals show Kedaara Capital buying 2 lakh shares at ₹1,654.90 (institutional accumulation), while Scott Hayworth sold an equal position at the same price (rebalance, not insider concern). The price action and flows suggest the market is digesting the Q2 beat but remains cautious on the FY28–29 guidance deferral — the 24% drawdown from the ATH is fair value for a stock that promises 15%+ CAGR but requires two years of integration before proof emerges.

What to watch next
  • 1 · Q3 FY27 (Dec 2026): ESOP impact and adjusted EBITDA modeling

    ESOP grant (~4% dilution) gets disclosed. Watch how adjusted EBITDA is impacted and whether management provides framework for stripping it out. If adjusted metrics deteriorate faster than expected, TruBridge margin ramp credibility weakens.

  • 2 · Q4 FY27 (Mar 2027): System of action features live in TruBridge EHR

    First three denial prevention, coding, and clinical documentation AI modules go live. Customer traction and early adoption metrics are the proof point for the 10–12% rural market TAM growth thesis. Slippage here ripples into FY28 guidance.

  • 3 · Q1 FY28 (Jun 2027): Project Endeavor rural market OS and system of intelligence launch

    Rural operating system for community hospitals and Project Endeavor go live. System of intelligence layer becomes commercially available. These are the catalysts that justify the FY30 INR 3,000 Cr EBITDA target. Execute cleanly or miss, and the market reprices the whole thesis.

Inventurus delivered a clean Q2 — revenue and margins on target, integration on schedule, patient data moat larger than expected. But management's explicit caution on FY28–29 TruBridge growth and refusal to uplift the FY30 EBITDA target despite self-described upside surprises is the real story. This is steady execution in the early innings of a multi-year integration, not a step-change. The stock is fairly valued at ₹1,665.5 given the 'show me' story ahead.

The verdict: Hold. Buy if and when Q4 FY27 system of action launch and Q1 FY28 Project Endeavor proof points de-risk the execution path. The number to track from here is TruBridge margin progression — each quarter watch whether adjusted EBITDA margin is trending toward the 21–22% target or staying flat near 17.5%. If it slips below 19% by mid-FY28, the margin accretion thesis fails, and the FY30 EBITDA target becomes unachievable. That's your downgrade trigger.

Informational and educational content only. Not investment advice.